Beyond A1c: Redefining Evidence and Policy to Advance Therapies in Type 1 Diabetes Care.

Source: PubMed, NCBI / U.S. National Library of Medicine

Innovation in technology has revolutionized modern-day type 1 diabetes (T1D) care, significantly improving glycaemic control and the patient experience. However, the outcome measures used in clinical trials, which inform policies, remain stagnant. Progress has been made in the search for adjunctive therapies beyond insulin to reduce residual cardiometabolic risk. The importance of patient-centred strategies is also increasingly recognized. The future of T1D research calls for the adaptation by regulators to accept additional endpoints beyond haemoglobin A1C (HbA1c).